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Abstract
Classical mitogen-activated protein kinases (MAPKs) play a pivotal role in a variety of cellular signal transduction
pathways. MAPKs are activated by phosphorylation at specific threonine and tyrosine residues catalyzed by upstream
MAPK kinases (MAPKKs). Mutations of these two activation phosphorylation sites into acidic amino acids, however, do
not convert MAPKs into constitutively active forms. Here, we report an approach to make a molecule with constitutive
MAPK activity. The nuclear export signal-disrupted, constitutively active MAPKK was fused to the N-terminal end of wild-
type MAPK. When the resulting fusion protein was expressed in Escherichia coli, the MAPK moiety became phosphorylated
and the fusion protein was constitutively active as MAPK. Moreover, when expressed in mammalian cultured cells, the
fusion protein was also activated as MAPK and was able to induce marked morphological changes in NIH-3T3 cells. These
results suggest that the fusion protein can work as constitutively active MAPK and that this approach may be applicable to
other members of the MAPK family to make constitutively active forms. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Various extracellular stimuli evoke cellular re-
sponses via activation of protein kinase cascades
[1,2]. Mitogen-activated protein kinases (MAPKs),
also known as the extracellular signal-regulated ki-
nases (ERKs), are serine/threonine protein kinases
that play pivotal roles in transmitting various cellular
signals to the nucleus. MAPKs can be activated di-
rectly by dual phosphorylation at threonine and ty-
rosine residues in the activation loop by upstream
dual speci¢city protein kinases, MAPK kinases
(MAPKKs) [3^10].
Constitutively active forms of proteins can be ef-
fectively used to analyze the physiological function of
the molecules. Many proteins that are activated by
phosphorylation have been reported to be arti¢cially
modi¢ed into constitutively active forms when an
amino acid(s) at the activating phosphorylation
site(s) is mutated to a phosphoamino acid-mimicking
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acidic amino acid(s). Phosphorylation of two adja-
cent Ser/Thr residues in the activation loop of
MAPKK (also known as MEK) is essential for its
activation and in fact, alteration of these residues to
acidic amino acids makes MAPKK constitutively ac-
tive [11,12]. Another prevailing way to produce con-
stitutively active proteins is deleting an inhibitory
domain from a full-length protein. This strategy is
applicable for proteins that possess a domain that
regulates the activity negatively. As a typical exam-
ple, Raf protein kinase possesses an inhibitory region
at its N-terminus and deletion of this region renders
Raf constitutively active [13].
Although MAPKs are known to be activated by
phosphorylation at the conserved TXY motif in the
activation loop [3^10], mutations of these phospho-
rylatable threonine and tyrosine residues to acidic
amino acids fail to convert MAPKs into constitu-
tively active forms. In addition, MAPKs are not
known to have negative regulatory domains, thus,
it is not easy to make MAPK constitutively active
by deleting some portion of the molecules. It is im-
portant and useful to produce constitutively active
forms of MAPKs not only for analyzing functions
of MAPKs in a variety of biological processes but
also for screening of drugs that inhibit the activated
MAPKs. Although a gain of function mutation of a
Drosophila MAPK homologue rolled was identi¢ed
[14], the kinase activity of the mutant was very low
[14,15] and the cause of the gain of function still
remains to be elucidated.
The intracellular distribution of MAPK is regu-
lated by its association with MAPKK [16]. Recently,
conserved nuclear export signals (NESs) have been
identi¢ed in many cytoplasmic proteins [17^19]. In
the N-terminal region, MAPKK has a NES [20]
that is responsible for cytoplasmic localization of
not only MAPKK itself but also MAPK [16]. More-
over, the association between MAPKK and MAPK
may enhance the e⁄ciency of signal transduction
from MAPKK to MAPK and assure its speci¢city
[21].
In this study, we report an approach to produce a
constitutively active form of MAPK. The idea is that
MAPK must be e⁄ciently phosphorylated and acti-
vated by MAPKK when MAPK locates adjacent to
constitutively active MAPKK. In addition, the NES
of MAPKK was disrupted to ensure that the fusion
protein resides within the nucleus to have biological
e¡ects. Recently, Cobb and colleagues reported an
achievement of constitutively active MAPK by mak-
ing a fusion protein between nuclear localizable
MEK1 and ERK2 [22].
2. Materials and methods
2.1. Plasmids, proteins, reagents and cell lines
cDNAs of Xenopus MAPK (wild-type and mu-
tants) and MAPKK (wild-type and mutants) were
described previously [16,20,23]. pGEX-6P for gluta-
thione-S-transferase (GST) fusion proteins and PreS-
cission protease were from Pharmacia. pEGFP-N1
for green £uorescent protein (GFP) expression was
from Clontech. Hemagglutinin (HA)-pcDNA3 is a
modi¢ed pcDNA3 vector (Invitrogen) containing a
HA-tag sequence. pTrx vector encoding the thiore-
doxin gene [24] was from Dr S. Ishii. Histone H1 and
dephosphorylated casein were from Sigma. Puri¢ed
myelin basic protein (MBP), GST-c-Jun and ATF2
were described previously [25]. Acid phosphatase was
from Boehringer Mannheim. All of the plasmids and
vectors were prepared and puri¢ed by anion-ex-
change columns (QIAGEN). COS7 cells and NIH-
3T3 cells were maintained in DMEM supplemented
with 10% fetal calf serum and 10% calf serum, re-
spectively.
2.2. Antibodies
Antibodies speci¢c for HA-tag, ERK1/2 and du-
ally phosphorylated MAPK were obtained from
Boehringer Mannheim, Santa Cruz and Promega,
respectively. Rabbit anti-MAPK (Xenopus) and
anti-MAPKK (Xenopus) antibodies were described
previously [16,26]. Horseradish peroxidase-conju-
gated secondary antibodies for Western blotting
were from Amersham.
2.3. Construction of the fusion protein
A cDNA encoding Xenopus MAPK was digested
by MspI (Toyobo) and ¢lled by T4 polymerase
(Takara). A cDNA encoding Xenopus MAPKK
was cut with A£II (Takara) and then, the protruded
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end was digested by Mung bean nuclease (Takara)
to obtain an in frame blunt-end fragment. These
DNA fragments were ligated, introduced into Es-
cherichia coli hosts and the plasmid encoding a single
fusion protein was recovered. The entire open read-
ing frame was then excised from the plasmid with
SmaI and NotI and inserted into the multi cloning
site of pGEX-6P for expression of the GST-
tagged fusion protein in E. coli. The coding region
was also inserted into HA-pcDNA3 to obtain a
mammalian expression vector of HA-tagged fusion
protein.
2.4. Expression and puri¢cation of recombinant fusion
protein
E. coli strain AD494(DE3) (Novagen), a thiore-
doxin reductase (trxB) de¢cient strain of
BL21(DE3), was ¢rst transformed with pTrx (thiore-
doxin) and competent cells obtained were further
transformed with the plasmid encoding the GST-
tagged fusion protein. After reaching an appropriate
density (OD600 = 0.6), cultures were supplemented
with 1 mM isopropyl L-D-thiogalactopyranoside
and further shaken for 24 h at 20‡C. The E. coli cells
were washed two times with phosphate-bu¡ered sal-
ine (PBS) and ruptured in PBS (supplemented with
1 mM ethylenediaminetetraacetic acid (EDTA),
1 mM phenylmethylsulfonyl £uoride (PMSF),
0.1 TIU/ml aprotinin and 10 Wg/ml leupeptin) by
two times freeze-thawing and then sonication. The
resulted extract was supplemented with ¢nal 1% Tri-
ton X-100 and clari¢ed by a centrifugation
(17 000Ug for 60 min at 4‡C). The extract was mixed
with glutathione-Sepharose (Pharmacia) for 3 h at
4‡C and the beads were washed extensively with
PBS containing 1% Triton X-100. The beads were
then treated overnight with PreScission protease
(40 U/ml) in a cleavage bu¡er (50 mM Tris-Cl,
150 mM NaCl, 1 mM EDTA and 1 mM dithiothrei-
tol (DTT), pH 7.0) and the fusion protein without
GST-tag was collected by centrifugation. The crude
fusion protein was further puri¢ed by column chro-
matography using a ResourceQ column (0^1000
mM NaCl gradient in a bu¡er containing 40 mM
Tris-Cl, 1 mM DTT and 1 mM EDTA, pH 7.4)
and dialyzed in the same bu¡er containing 150 mM
NaCl.
2.5. Expression of tagged fusion proteins in
mammalian cells
HA-pcDNA3 containing the open reading frame
of MAPKK*-MAPK (see Section 3) was introduced
into COS7 cells by electroporation (Bio-Rad, 230 V/
960 WF, 0.4 cm gap). After 2 days, cells were washed
with PBS and solubilized in 400 Wl per dish of IPW
bu¡er (50 mM Tris-Cl, 50 mM NaCl, 100 mM NaF,
10% glycerol, 2 mM EDTA, 2 mM sodium orthova-
nadate, 10 mM sodium pyrophosphate, 1 mM di-
thiothreitol and 1% Nonidet-P40, pH 8.0), supple-
mented with 0.1 TIU/ml aprotinin, 10 Wg/ml
leupeptin and 1 mM PMSF. The lysates were then
centrifuged at 17 000Ug for 60 min at 2‡C and
supernatants were recovered as cell extracts. NIH-
3T3 cells were transfected with the mammalian ex-
pression vector described above, 1 day after plated
using LipofectoAMINE PLUS Reagents (Gibco) in
serum-free Opti-MEM medium. After 3 h exposure
to DNA, medium was changed to DMEM+10% calf
serum and further cultured for 24 h before micro-
scopic examination.
2.6. Immunoprecipitation
The equal amounts of cell extracts (1 mg proteins)
were precleared by mixing with non-immune serum
(2 Wl), protein G-Sepharose (Pharmacia, 15 Wl) and
OmniSorb suspension (Calbiochem, 300 Wl). The pre-
cleared lysates were mixed with antibodies against
HA-tag (4 Wg) and rotated overnight at 4‡C. 15 Wl
of the protein G-Sepharose was added and further
incubated at 4‡C for 90 min. The antibody-bound
beads were washed with IPW bu¡er for ¢ve times
and used for the in vitro protein kinase assay.
2.7. In vitro protein kinase assay
10 Wl of the immunoprecipitates or 1 Wg of the
puri¢ed kinase was incubated in a kinase assay mix-
ture at 30‡C for 60 min with continuous mixing (to-
tal volume of 30 Wl). The ¢nal composition of the
kinase assay mixture was 50 mM Tris-Cl, 100 mM
NaCl, 10 mM MgCl2, 1 mM MnCl2, 0.03 mM
(0.1 MBq) ATP and 20 Wg of a protein substrate,
pH 7.4. To stop the reaction, 10 Wl of the sodium
dodecyl sulfate (SDS) sample bu¡er was added and
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mixtures were boiled for 5 min. The phosphorylation
of the proteins was analyzed by SDS-polyacrylamide
gel electrophoresis (PAGE) and autoradiography.
2.8. Phosphatase treatment
0.1 Wg of puri¢ed fusion protein was mixed with
0.04 U (V0.7 Wg) of potato acid phosphatase in an
acidic bu¡er (50 mM ammonium acetate, 10 mM
MgCl2 and 20% glycerol, pH 5.5) and incubated
for 60 min at 30‡C. An aliquot was removed for
analysis and one ¢fth volume of a high pH bu¡er
(100 mM Tris-Cl, 100 mM MgCl2 and 1 mM DTT,
pH 7.5) was added, then, the mixture was further
incubated 15 min at 30‡C with 0.2 mM (¢nal) of
ATP in the presence of phosphatase inhibitors
(1 WM sodium orthovanadate and 1 WM okadaic
acid).
3. Results
3.1. Strategy to make constitutively active MAPK
The strategy to construct constitutively active
MAPK is schematically illustrated in Fig. 1. We
Fig. 2. Spontaneous MAPK activating phosphorylation of
MAPKK*-MAPK in E. coli. (A) CBB staining of partially pu-
ri¢ed MAPKK*-MAPK fusion protein expressed in E. coli. (B)
Reactivity of MAPKK*-MAPK fusion protein with anti-
MAPK (top), anti-MAPKK (middle) or anti-dually phosphoryl-
ated MAPK (anti-phosphoMAPK, bottom) antibodies. Lane 1,
MAPKK*-MAPK(WT); lane 2, MAPKK*-MAPK(KD).
Fig. 1. Schematic illustration of the constitutively activated
MAPK engineering. Ser-218 and Ser-222 of Xenopus MAPKK
were changed to Asp and Glu, respectively, to make MAPKK
constitutively active. Leu-33 and Leu-37 were mutated to Ala
to disrupt a NES in MAPKK. An obtained MAPKK mutant
(MAPKK*) was fused in frame to a Xenopus MAPK fragment.
The fusion protein (MAPKK*-MAPK(WT)) is a single poly-
peptide containing MAPKK* at the N-terminal and MAPK at
the C-terminus. Very short segments from both MAPKK and
MAPK were removed during the construction as illustrated. As
a negative control, the lysine residue essential for MAPK activ-
ity was mutated into Asp (MAPKK*-MAPK(KD)).
Fig. 3. Constitutive MAPK activity of MAPKK*-MAPK ex-
pressed in E. coli. MAPKK*-MAPK(KD) (left, lanes 1^6) or
MAPKK*-MAPK(WT) (right, lanes 7^12) fusion protein was
expressed in E. coli and puri¢ed. The fusion proteins were incu-
bated with various indicated substrate proteins in the presence
of radio-labelled ATP and the autoradiogram of SDS-PAGE
was shown. The substrates used were ATF2 (lanes 2 and 8),
GST-c-Jun (lanes 3 and 9), MBP (lanes 4 and 10), casein (lanes
5 and 11) and histone (lanes 6 and 12). Phosphorylation with-
out exogenous substrate was also performed (lanes 1 and 7).
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have previously described a constitutively active,
NES-disrupted MAPKK whose kinase activity is
strongest among various MAPKK mutants [23,27].
From the entire open reading frame (395 amino
acids) of this mutant MAPKK, we cut out a frag-
ment (amino acid 1^382) which is denoted as
‘MAPKK*‘ hereafter. This fragment was fused in
frame to the 5P end of a cDNA fragment encoding
Xenopus MAPK that lacks the N-terminal 12 amino
acids. The resulted fusion DNA encodes a single
polypeptide (MAPKK*-MAPK(WT)) with 730 ami-
no acids containing constitutively active MAPKK at
its N-terminal half and wild-type MAPK at its C-
terminal half (Fig. 1). The lysine residue essential
for kinase activity of MAPK (lysine 57 in the origi-
nal MAPK subdomain II) was mutated into Asp to
obtain MAPKK*-MAPK(KD), a kinase de¢cient
negative control (Fig. 1).
3.2. Constitutive activity of the recombinant fusion
protein in vitro
First, MAPKK*-MAPK was expressed as GST-
tagged protein in E. coli. Among various conditions
tested, we found that co-transformation with a thio-
redoxin expression vector [24] in a thioredoxin reduc-
tase de¢cient host was optimal for the production
and recovery of the fusion protein. Lower temper-
atures were preferable and we cultured E. coli at
Fig. 5. Spontaneous MAPK activating phosphorylation of MAPKK*-MAPK expressed in COS7 cells. MAPKK*-MAPK(WT) (lane
2) or MAPKK*-MAPK(KD) (lane 3) was expressed in COS7 cells and the total cell lysates were probed with antibodies speci¢c for
(A) MAPK, (B) MAPKK, (C) dually phosphorylated MAPK (phosphoMAPK). Positions of endogenous MAPK (ERK1/2) and
MAPKK were indicated by arrowheads and the positions of the fusion proteins were indicated by arrows. The control COS7 lysates
without transfection were also examined (lane 1).
Fig. 4. E¡ect of dephosphorylation and re-phosphorylation on
the state of the MAPK moiety of MAPKK*-MAPK(WT). Par-
tially puri¢ed bacterially expressed MAPKK*-MAPK(WT) was
probed with antibody speci¢c for dually phosphorylated active
MAPK (anti-phosphoMAPK). Lane 1, MAPKK*-MAPK(WT)
without treatment; lane 2, MAPKK*-MAPK(WT) was treated
with acid phosphatase; lane 3, after acid phosphatase treat-
ment, ATP was added in the presence of phosphatase inhibi-
tors. A lower panel indicates amounts of the fusion protein
shown by CBB staining.
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20‡C after induction. The expression was readily de-
tectable by Coomassie brilliant blue (CBB) staining
of total E. coli lysates as a 110 kDa protein band
(including GST-tag) as expected from its DNA size
(data not shown). The recombinant MAPKK*-
MAPK fusion protein was puri¢ed from E. coli ly-
sates as described under Section 2. The puri¢ed fu-
sion protein was observed as an 80 kDa major band
(without GST-tag) with a slightly smaller proteolytic
fragment (Fig. 2A). This 80 kDa polypeptide was
recognized by both anti-MAPK antibody (Fig. 2B,
top) and anti-MAPKK antibody (Fig. 2B, middle),
con¢rming that the protein contained both MAPK
and MAPKK moieties. Interestingly, the recombi-
nant fusion protein was strongly reacted with an
antibody that speci¢cally recognizes doubly phos-
phorylated active MAPK (Fig. 2B, bottom). This
result indicated that the fusion protein was doubly
phosphorylated in the activation loop of the MAPK
moiety. The phosphorylation was also seen in the
kinase de¢cient mutant of the fusion protein,
MAPKK*-MAPK(KD) (lane 2), indicating that au-
tophosphorylating kinase activity of MAPK was not
responsible for the activating phosphorylation.
The kinase activity of the MAPKK*-MAPK fu-
sion protein was examined by incubating with vari-
ous protein kinase substrates in the presence of ra-
diolabelled ATP. The fusion protein phosphorylated
known MAPK substrates tested (ATF2, c-Jun and
MBP), but only very weakly phosphorylated other
substrates (casein and histone) (Fig. 3, right, lanes
7^12). This result indicated that the substrate specif-
icity of the fusion kinase was similar to that of
MAPK. In contrast to MAPKK*-MAPK(WT),
MAPKK*-MAPK(KD) did not show signi¢cant kin-
ase activity towards these substrates (Fig. 3, left,
lanes 1^6), indicating that the observed constitutive
kinase activity was derived from the MAPK moiety
of MAPKK*-MAPK. As reported previously [28],
no kinase activity could be recovered from E. coli
that expressed MAPK only (data not shown). Since
no MAPKK was expressed in E. coli, the results in
Figs. 2 and 3 suggest that the MAPKK portion of
the fusion protein phosphorylated and activated the
MAPK part spontaneously in E. coli cells.
We then performed a phosphatase treatment. As
expected, phosphatase treatment greatly diminished
the reactivity of puri¢ed fusion protein to anti-dually
phosphorylated MAPK (Fig. 4, compare lanes 1 and
2). When we then added ATP exogenously in the
presence of phosphatase inhibitors, the amount of
dually phosphorylated MAPK of the fusion protein
recovered signi¢cantly as revealed by Western blot-
ting with anti-phosphoMAPK (Fig. 4, compare lanes
2 and 3). This result con¢rmed that the active form
of the fusion protein could be spontaneously
achieved by phosphorylation of the MAPK part
with the MAPKK moiety.
3.3. Constitutive activity of the fusion protein in cells
Next, we expressed the MAPKK*-MAPK fusion
protein in COS7 cells to see the constitutive activity
in mammalian cells. As expected, the expressed fu-
sion protein was recognized by anti-MAPK (Fig. 5A)
and by anti-MAPKK (Fig. 5B, shown by arrows),
only in the transfected cell lysates. The amount of
Fig. 6. Constitutive MAPK activity of MAPKK*-MAPK(WT)
expressed in mammalian cells. The fusion proteins were ex-
pressed in COS7 cells by transfection and immunoprecipitated
with anti-HA-tag antibody. The immunoprecipitates were incu-
bated with [Q-32P]ATP and MBP and the mixtures were ana-
lyzed by SDS-PAGE followed by CBB staining (A) or by auto-
radiography (B). The positions of the fusion protein and MBP
were shown. Immunoprecipitates from un-transfected COS7
(lane 1), from COS7 cells transfected with MAPKK*-
MAPK(WT) (lane 2) or from COS7 cells transfected with
MAPKK*-MAPK(KD) (lane 3) are shown.
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expressed fusion protein was comparable to that of
endogenous MAPK (ERK1/2) and was higher than
that of endogenous MAPKK. Importantly, the ex-
pressed fusion protein was far more strongly stained
than endogenous MAPK by the antibody speci¢c for
doubly phosphorylated active MAPK (Fig. 5C), sug-
gesting the spontaneous (probably intramolecular)
phosphorylation of the fusion protein at the
MAPK activating site in mammalian cells.
MAPKK*-MAPK(KD) was also heavily stained
with the anti-phosphoMAPK (lane 3). This result
again indicates that MAPK autophosphorylation
was not responsible for the phosphorylation and ac-
tivation of the fusion protein. The increase of the
phosphorylated (i.e. activated) forms of endogenous
MAPKs was minimum (Fig. 5C), showing that the
MAPKK portion of the expressed fusion protein did
not signi¢cantly induce the activation of endogenous
MAPK. In other words, the constitutively active
MAPKK in the fusion protein appears to phospho-
rylate the MAPK moiety of the same molecule much
more e⁄ciently than endogenous MAPK. Thus, we
can assume that the e¡ect of the expression of the
fusion protein could be mainly attributable to the
constitutive MAPK activity, but not to MAPKK ac-
tivity, of the fusion protein.
The MAPK activity of the fusion protein was ex-
amined in vitro using MBP as a substrate after im-
munoprecipitation with anti-HA-tag antibody. As
shown in Fig. 6B the immunoprecipitate from cells
transfected with MAPKK*-MAPK(WT) exhibited
strong constitutive MAPK activity. In contrast, the
immunoprecipitate from cells transfected with
MAPKK*-MAPK(KD) or from control un-trans-
Fig. 7. Morphological transformation by the fusion protein in NIH-3T3 cells. NIH-3T3 cells were transfected with expression vectors
encoding the indicated proteins along with GFP-expressing vector as a transfection marker. The cells were observed by a £uorescence
microscope to see expressed GFP to identify transfected cells (left) or by a phase contrast microscope (right) to see the cell morphol-
ogy. Cells transfected with MAPK (A and B), MAPKK* (C and D) or MAPKK*-MAPK(WT) (E and F) are shown.
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fected cells showed no MAPK activity (Fig. 6B, lanes
1 and 3). Almost equal amounts of immunoprecipi-
tated fusion proteins were visible by CBB staining
for both MAPKK*-MAPK(WT) and MAPKK*-
MAPK(KD) (Fig. 6A). Taken together, we con-
cluded that the MAPKK*-MAPK fusion protein
underwent spontaneous self-phosphorylation
(MAPKK* phosphorylates MAPK in the fusion pro-
tein) in vivo and was constitutively active as MAPK.
3.4. Morphological changes induced by the fusion
protein
We have been interested in the e¡ect of expression
of the constitutive MAPK activity in mammalian
cells. Expression vectors were mixed with a GFP
vector as a transfection marker and introduced in
NIH-3T3 cells. The transfected cells could be identi-
¢ed by GFP £uorescence (Fig. 7, left). Cell morphol-
ogy was examined under the phase contrast micro-
scope (Fig. 7, right). NIH-3T3 cells that expressed
only MAPK showed a normal £at phenotype as
seen in Fig. 7A and B. When transfected with
MAPKK* alone, a portion of the expressed cells
became rounded, but about a half of the expressed
cells remained as relatively normal spindle-like
shapes under the conditions (Fig. 7C and D). This
e¡ect could be attributed to the limited activation of
endogenous MAPK by MAPKK* expression (see
Fig. 5C). Interestingly, almost all of the cells that
expressed MAPKK*-MAPK(WT) exhibited a com-
pletely rounded transformed morphology (Fig. 7E
and F). No change of morphology could be observed
when the kinase de¢cient version of the fusion pro-
tein, MAPKK*-MAPK(KD), was expressed (data
not shown). As expected by the NES disruptive mu-
tation, most of the expressed fusion protein was dis-
tributed within the nucleus as well as cytoplasm
when revealed by anti-HA staining (data not shown).
Taken together, we concluded that the fusion protein
possesses the constitutive MAPK activity when ex-
pressed in mammalian cells.
4. Discussion
All of the above results clearly show that the
fusion protein between constitutively active MAPKK
and wild-type MAPK can work as constitutively ac-
tive MAPK. This constitutive activation could be
observed both in E. coli and in mammalian cells.
Although the precise mechanism of the spontaneous
activation remains to be clari¢ed, it is not unlikely to
postulate intramolecular phosphorylation of the
MAPK moiety by the MAPKK portion of the fusion
protein. This mechanism should ensure the speci¢city
and enhance the e⁄ciency of activation, avoiding
possible cross-talks between several similar
MAPKK-MAPK pathways. It would be worth pro-
ducing fusion proteins between other members of the
MAPK family and corresponding constitutively ac-
tive MAPKKs.
During the course of this study, Robinson et al.
reported a similar approach to make a constitutively
active MAPK [22]. They made a fusion protein be-
tween ERK2 and a nuclear localizing mutant of
MEK1 and observed the constitutive MAPK activity
of the fusion protein [22]. There are several di¡er-
ences between their approach and our strategy de-
scribed here: (i) they constructed a fusion with
MAPK at the N-terminal half while we put MAPKK
at the N-terminal, (ii) they used an NES-disrupted,
non-constitutively active MAPKK (whose activity is
low), but we used an NES-disrupted, constitutively
active MAPKK (whose activity is much stronger),
(iii) they inserted an intervening Glu-Gly linker while
we directly conjugated MAPKK with MAPK, (iv)
our fusion protein can be produced in E. coli as a
recombinant active kinase. Despite these di¡erences,
the major results obtained were similar. It is di⁄cult
to directly compare the level of the constitutive ac-
tivity between these two di¡erent systems. One of the
advantages of our strategy is that the fusion protein
can be e¡ectively and spontaneously activated when
expressed and puri¢ed in E. coli. Until now, acti-
vated MAPK has only been available by phospho-
rylating puri¢ed MAPK with isolated MAPKK in
vitro [28,29] or by co-expressing both MAPKK and
MAPK separately in cells [30,31]. It will be an ad-
vantage for biochemical use to have a large amount
of recombinant constitutively active MAPK from a
single plasmid. In addition, the bacterial host that
possesses constitutive MAPK activity can be used
for other purposes such as screening of inhibitors.
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